nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—GSTP1—Carboplatin—esophageal cancer	0.272	0.496	CbGbCtD
Clomipramine—GSTP1—Cisplatin—esophageal cancer	0.232	0.424	CbGbCtD
Clomipramine—ABCB1—esophageal cancer	0.187	1	CbGaD
Clomipramine—HRH2—gastric juice—esophageal cancer	0.0212	0.395	CbGeAlD
Clomipramine—ALB—Methotrexate—esophageal cancer	0.0189	0.0344	CbGbCtD
Clomipramine—ABCB1—Cisplatin—esophageal cancer	0.0152	0.0277	CbGbCtD
Clomipramine—ABCB1—Methotrexate—esophageal cancer	0.00987	0.018	CbGbCtD
Clomipramine—HTR2A—vagus nerve—esophageal cancer	0.00362	0.0672	CbGeAlD
Clomipramine—GSTP1—exocrine gland—esophageal cancer	0.00282	0.0524	CbGeAlD
Clomipramine—GSTP1—neck—esophageal cancer	0.0018	0.0335	CbGeAlD
Clomipramine—HRH2—digestive system—esophageal cancer	0.0013	0.0241	CbGeAlD
Clomipramine—GSTP1—epithelium—esophageal cancer	0.00123	0.0228	CbGeAlD
Clomipramine—GSTP1—bronchus—esophageal cancer	0.00121	0.0224	CbGeAlD
Clomipramine—GSTP1—smooth muscle tissue—esophageal cancer	0.00118	0.0219	CbGeAlD
Clomipramine—GSTP1—trachea—esophageal cancer	0.00108	0.0201	CbGeAlD
Clomipramine—HRH2—lung—esophageal cancer	0.00108	0.0201	CbGeAlD
Clomipramine—HTR2B—smooth muscle tissue—esophageal cancer	0.000974	0.0181	CbGeAlD
Clomipramine—GSTP1—digestive system—esophageal cancer	0.000933	0.0173	CbGeAlD
Clomipramine—HTR2A—neck—esophageal cancer	0.000793	0.0147	CbGeAlD
Clomipramine—GSTP1—lung—esophageal cancer	0.000779	0.0145	CbGeAlD
Clomipramine—SLC6A4—digestive system—esophageal cancer	0.000776	0.0144	CbGeAlD
Clomipramine—HTR2B—digestive system—esophageal cancer	0.000769	0.0143	CbGeAlD
Clomipramine—HRH2—lymph node—esophageal cancer	0.00074	0.0137	CbGeAlD
Clomipramine—SLC6A4—lung—esophageal cancer	0.000648	0.012	CbGeAlD
Clomipramine—CYP2C19—digestive system—esophageal cancer	0.000643	0.0119	CbGeAlD
Clomipramine—HTR2B—lung—esophageal cancer	0.000642	0.0119	CbGeAlD
Clomipramine—ADRA2A—bronchus—esophageal cancer	0.000625	0.0116	CbGeAlD
Clomipramine—SLC6A2—lung—esophageal cancer	0.000571	0.0106	CbGeAlD
Clomipramine—ADRA2A—trachea—esophageal cancer	0.000561	0.0104	CbGeAlD
Clomipramine—HTR2A—epithelium—esophageal cancer	0.00054	0.01	CbGeAlD
Clomipramine—GSTP1—lymph node—esophageal cancer	0.000533	0.0099	CbGeAlD
Clomipramine—CYP1A2—digestive system—esophageal cancer	0.000525	0.00976	CbGeAlD
Clomipramine—HTR2A—smooth muscle tissue—esophageal cancer	0.00052	0.00966	CbGeAlD
Clomipramine—HTR2A—trachea—esophageal cancer	0.000477	0.00887	CbGeAlD
Clomipramine—ALB—lymph node—esophageal cancer	0.000456	0.00848	CbGeAlD
Clomipramine—HTR2B—lymph node—esophageal cancer	0.000439	0.00816	CbGeAlD
Clomipramine—CYP1A2—lung—esophageal cancer	0.000439	0.00815	CbGeAlD
Clomipramine—HTR2A—digestive system—esophageal cancer	0.000411	0.00763	CbGeAlD
Clomipramine—ADRA2A—lung—esophageal cancer	0.000403	0.00749	CbGeAlD
Clomipramine—SLC6A2—lymph node—esophageal cancer	0.00039	0.00725	CbGeAlD
Clomipramine—CYP3A4—digestive system—esophageal cancer	0.00038	0.00706	CbGeAlD
Clomipramine—CYP2D6—digestive system—esophageal cancer	0.000374	0.00695	CbGeAlD
Clomipramine—ABCB1—epithelium—esophageal cancer	0.000354	0.00657	CbGeAlD
Clomipramine—HTR2A—lung—esophageal cancer	0.000343	0.00637	CbGeAlD
Clomipramine—ABCB1—trachea—esophageal cancer	0.000313	0.00581	CbGeAlD
Clomipramine—ADRA2A—lymph node—esophageal cancer	0.000276	0.00513	CbGeAlD
Clomipramine—ABCB1—digestive system—esophageal cancer	0.000269	0.005	CbGeAlD
Clomipramine—Urine output increased—Methotrexate—esophageal cancer	0.00026	0.0023	CcSEcCtD
Clomipramine—Bladder pain—Methotrexate—esophageal cancer	0.00026	0.0023	CcSEcCtD
Clomipramine—Mouth ulceration—Methotrexate—esophageal cancer	0.00026	0.0023	CcSEcCtD
Clomipramine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00026	0.0023	CcSEcCtD
Clomipramine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000258	0.00229	CcSEcCtD
Clomipramine—Urethral disorder—Cisplatin—esophageal cancer	0.000258	0.00228	CcSEcCtD
Clomipramine—Gynaecomastia—Methotrexate—esophageal cancer	0.000257	0.00228	CcSEcCtD
Clomipramine—Dry skin—Capecitabine—esophageal cancer	0.000257	0.00227	CcSEcCtD
Clomipramine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000256	0.00227	CcSEcCtD
Clomipramine—Hypokalaemia—Capecitabine—esophageal cancer	0.000255	0.00226	CcSEcCtD
Clomipramine—Visual impairment—Cisplatin—esophageal cancer	0.000253	0.00224	CcSEcCtD
Clomipramine—Breast disorder—Capecitabine—esophageal cancer	0.000253	0.00224	CcSEcCtD
Clomipramine—Gastritis—Capecitabine—esophageal cancer	0.000248	0.0022	CcSEcCtD
Clomipramine—Muscular weakness—Capecitabine—esophageal cancer	0.000247	0.00219	CcSEcCtD
Clomipramine—Eye disorder—Cisplatin—esophageal cancer	0.000246	0.00218	CcSEcCtD
Clomipramine—Tinnitus—Cisplatin—esophageal cancer	0.000245	0.00217	CcSEcCtD
Clomipramine—Lymphadenopathy—Methotrexate—esophageal cancer	0.000245	0.00217	CcSEcCtD
Clomipramine—Cardiac disorder—Cisplatin—esophageal cancer	0.000244	0.00216	CcSEcCtD
Clomipramine—Flushing—Cisplatin—esophageal cancer	0.000244	0.00216	CcSEcCtD
Clomipramine—Dysphagia—Capecitabine—esophageal cancer	0.000242	0.00215	CcSEcCtD
Clomipramine—Thrombophlebitis—Methotrexate—esophageal cancer	0.000241	0.00213	CcSEcCtD
Clomipramine—Diabetes mellitus—Methotrexate—esophageal cancer	0.00024	0.00212	CcSEcCtD
Clomipramine—Bronchospasm—Capecitabine—esophageal cancer	0.000238	0.00211	CcSEcCtD
Clomipramine—Photosensitivity—Methotrexate—esophageal cancer	0.000238	0.0021	CcSEcCtD
Clomipramine—Polyuria—Methotrexate—esophageal cancer	0.000238	0.0021	CcSEcCtD
Clomipramine—Immune system disorder—Cisplatin—esophageal cancer	0.000238	0.0021	CcSEcCtD
Clomipramine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000237	0.0021	CcSEcCtD
Clomipramine—Sweating increased—Capecitabine—esophageal cancer	0.000236	0.00209	CcSEcCtD
Clomipramine—Arrhythmia—Cisplatin—esophageal cancer	0.000235	0.00208	CcSEcCtD
Clomipramine—Bronchitis—Capecitabine—esophageal cancer	0.000233	0.00206	CcSEcCtD
Clomipramine—Alopecia—Cisplatin—esophageal cancer	0.000232	0.00206	CcSEcCtD
Clomipramine—Pancytopenia—Capecitabine—esophageal cancer	0.00023	0.00204	CcSEcCtD
Clomipramine—Malnutrition—Cisplatin—esophageal cancer	0.000229	0.00203	CcSEcCtD
Clomipramine—Dysuria—Capecitabine—esophageal cancer	0.000227	0.00201	CcSEcCtD
Clomipramine—Flatulence—Cisplatin—esophageal cancer	0.000226	0.002	CcSEcCtD
Clomipramine—ABCB1—lung—esophageal cancer	0.000225	0.00418	CbGeAlD
Clomipramine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000221	0.00196	CcSEcCtD
Clomipramine—Weight increased—Capecitabine—esophageal cancer	0.00022	0.00195	CcSEcCtD
Clomipramine—Muscle spasms—Cisplatin—esophageal cancer	0.00022	0.00195	CcSEcCtD
Clomipramine—Weight decreased—Capecitabine—esophageal cancer	0.000219	0.00194	CcSEcCtD
Clomipramine—Hyperglycaemia—Capecitabine—esophageal cancer	0.000219	0.00194	CcSEcCtD
Clomipramine—Pneumonia—Capecitabine—esophageal cancer	0.000217	0.00192	CcSEcCtD
Clomipramine—Vision blurred—Cisplatin—esophageal cancer	0.000216	0.00191	CcSEcCtD
Clomipramine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000216	0.00191	CcSEcCtD
Clomipramine—Depression—Capecitabine—esophageal cancer	0.000215	0.00191	CcSEcCtD
Clomipramine—Tremor—Cisplatin—esophageal cancer	0.000215	0.0019	CcSEcCtD
Clomipramine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000213	0.00189	CcSEcCtD
Clomipramine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000213	0.00189	CcSEcCtD
Clomipramine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000212	0.00188	CcSEcCtD
Clomipramine—Myocardial infarction—Capecitabine—esophageal cancer	0.000212	0.00187	CcSEcCtD
Clomipramine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000212	0.00187	CcSEcCtD
Clomipramine—Anaemia—Cisplatin—esophageal cancer	0.000212	0.00187	CcSEcCtD
Clomipramine—Jaundice—Capecitabine—esophageal cancer	0.000211	0.00186	CcSEcCtD
Clomipramine—Urinary tract infection—Capecitabine—esophageal cancer	0.00021	0.00186	CcSEcCtD
Clomipramine—Conjunctivitis—Capecitabine—esophageal cancer	0.00021	0.00186	CcSEcCtD
Clomipramine—Osteoarthritis—Methotrexate—esophageal cancer	0.000209	0.00185	CcSEcCtD
Clomipramine—Malaise—Cisplatin—esophageal cancer	0.000206	0.00183	CcSEcCtD
Clomipramine—Haematuria—Capecitabine—esophageal cancer	0.000206	0.00182	CcSEcCtD
Clomipramine—Leukopenia—Cisplatin—esophageal cancer	0.000205	0.00181	CcSEcCtD
Clomipramine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000204	0.00181	CcSEcCtD
Clomipramine—Epistaxis—Capecitabine—esophageal cancer	0.000204	0.0018	CcSEcCtD
Clomipramine—Agranulocytosis—Capecitabine—esophageal cancer	0.000202	0.00178	CcSEcCtD
Clomipramine—Irritability—Methotrexate—esophageal cancer	0.000199	0.00176	CcSEcCtD
Clomipramine—Convulsion—Cisplatin—esophageal cancer	0.000198	0.00176	CcSEcCtD
Clomipramine—Mood swings—Methotrexate—esophageal cancer	0.000198	0.00175	CcSEcCtD
Clomipramine—Bradycardia—Capecitabine—esophageal cancer	0.000197	0.00175	CcSEcCtD
Clomipramine—Ataxia—Methotrexate—esophageal cancer	0.000196	0.00174	CcSEcCtD
Clomipramine—Myalgia—Cisplatin—esophageal cancer	0.000195	0.00173	CcSEcCtD
Clomipramine—Rhinitis—Capecitabine—esophageal cancer	0.000194	0.00172	CcSEcCtD
Clomipramine—Anxiety—Cisplatin—esophageal cancer	0.000194	0.00172	CcSEcCtD
Clomipramine—Hepatitis—Capecitabine—esophageal cancer	0.000194	0.00172	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000194	0.00171	CcSEcCtD
Clomipramine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000193	0.00171	CcSEcCtD
Clomipramine—Discomfort—Cisplatin—esophageal cancer	0.000193	0.00171	CcSEcCtD
Clomipramine—Pharyngitis—Capecitabine—esophageal cancer	0.000192	0.0017	CcSEcCtD
Clomipramine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000191	0.0017	CcSEcCtD
Clomipramine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000191	0.00169	CcSEcCtD
Clomipramine—Urethral disorder—Capecitabine—esophageal cancer	0.00019	0.00168	CcSEcCtD
Clomipramine—Breast disorder—Methotrexate—esophageal cancer	0.000189	0.00167	CcSEcCtD
Clomipramine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000187	0.00165	CcSEcCtD
Clomipramine—Oedema—Cisplatin—esophageal cancer	0.000187	0.00165	CcSEcCtD
Clomipramine—Visual impairment—Capecitabine—esophageal cancer	0.000187	0.00165	CcSEcCtD
Clomipramine—Nervous system disorder—Cisplatin—esophageal cancer	0.000183	0.00162	CcSEcCtD
Clomipramine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000183	0.00162	CcSEcCtD
Clomipramine—Tachycardia—Cisplatin—esophageal cancer	0.000182	0.00162	CcSEcCtD
Clomipramine—Skin disorder—Cisplatin—esophageal cancer	0.000182	0.00161	CcSEcCtD
Clomipramine—Eye disorder—Capecitabine—esophageal cancer	0.000181	0.0016	CcSEcCtD
Clomipramine—Tinnitus—Capecitabine—esophageal cancer	0.000181	0.0016	CcSEcCtD
Clomipramine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000181	0.0016	CcSEcCtD
Clomipramine—Flushing—Capecitabine—esophageal cancer	0.00018	0.00159	CcSEcCtD
Clomipramine—Cardiac disorder—Capecitabine—esophageal cancer	0.00018	0.00159	CcSEcCtD
Clomipramine—Eosinophilia—Methotrexate—esophageal cancer	0.000179	0.00158	CcSEcCtD
Clomipramine—Flurazepam—CYP2A6—esophageal cancer	0.000178	0.125	CrCbGaD
Clomipramine—Anorexia—Cisplatin—esophageal cancer	0.000178	0.00158	CcSEcCtD
Clomipramine—Angiopathy—Capecitabine—esophageal cancer	0.000176	0.00156	CcSEcCtD
Clomipramine—Immune system disorder—Capecitabine—esophageal cancer	0.000175	0.00155	CcSEcCtD
Clomipramine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000175	0.00155	CcSEcCtD
Clomipramine—Hypotension—Cisplatin—esophageal cancer	0.000175	0.00155	CcSEcCtD
Clomipramine—Chills—Capecitabine—esophageal cancer	0.000174	0.00154	CcSEcCtD
Clomipramine—Arrhythmia—Capecitabine—esophageal cancer	0.000173	0.00153	CcSEcCtD
Clomipramine—Alopecia—Capecitabine—esophageal cancer	0.000171	0.00152	CcSEcCtD
Clomipramine—Pancytopenia—Methotrexate—esophageal cancer	0.000171	0.00152	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00017	0.00151	CcSEcCtD
Clomipramine—Mental disorder—Capecitabine—esophageal cancer	0.00017	0.0015	CcSEcCtD
Clomipramine—Malnutrition—Capecitabine—esophageal cancer	0.000169	0.00149	CcSEcCtD
Clomipramine—Dysuria—Methotrexate—esophageal cancer	0.000169	0.00149	CcSEcCtD
Clomipramine—Paraesthesia—Cisplatin—esophageal cancer	0.000168	0.00149	CcSEcCtD
Clomipramine—Dyspnoea—Cisplatin—esophageal cancer	0.000167	0.00148	CcSEcCtD
Clomipramine—Flatulence—Capecitabine—esophageal cancer	0.000166	0.00147	CcSEcCtD
Clomipramine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000166	0.00147	CcSEcCtD
Clomipramine—Dysgeusia—Capecitabine—esophageal cancer	0.000165	0.00146	CcSEcCtD
Clomipramine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000165	0.00146	CcSEcCtD
Clomipramine—Back pain—Capecitabine—esophageal cancer	0.000163	0.00145	CcSEcCtD
Clomipramine—Decreased appetite—Cisplatin—esophageal cancer	0.000162	0.00144	CcSEcCtD
Clomipramine—Muscle spasms—Capecitabine—esophageal cancer	0.000162	0.00144	CcSEcCtD
Clomipramine—Pneumonia—Methotrexate—esophageal cancer	0.000162	0.00143	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000161	0.00143	CcSEcCtD
Clomipramine—Drowsiness—Methotrexate—esophageal cancer	0.000161	0.00142	CcSEcCtD
Clomipramine—Depression—Methotrexate—esophageal cancer	0.00016	0.00142	CcSEcCtD
Clomipramine—Pain—Cisplatin—esophageal cancer	0.00016	0.00142	CcSEcCtD
Clomipramine—Vision blurred—Capecitabine—esophageal cancer	0.000159	0.00141	CcSEcCtD
Clomipramine—Tremor—Capecitabine—esophageal cancer	0.000158	0.0014	CcSEcCtD
Clomipramine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000157	0.00139	CcSEcCtD
Clomipramine—Conjunctivitis—Methotrexate—esophageal cancer	0.000156	0.00138	CcSEcCtD
Clomipramine—Anaemia—Capecitabine—esophageal cancer	0.000156	0.00138	CcSEcCtD
Clomipramine—Desipramine—CYP2A6—esophageal cancer	0.000154	0.108	CrCbGaD
Clomipramine—Sweating—Methotrexate—esophageal cancer	0.000154	0.00136	CcSEcCtD
Clomipramine—Feeling abnormal—Cisplatin—esophageal cancer	0.000154	0.00136	CcSEcCtD
Clomipramine—ABCB1—lymph node—esophageal cancer	0.000154	0.00286	CbGeAlD
Clomipramine—Haematuria—Methotrexate—esophageal cancer	0.000153	0.00136	CcSEcCtD
Clomipramine—Malaise—Capecitabine—esophageal cancer	0.000152	0.00135	CcSEcCtD
Clomipramine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000152	0.00135	CcSEcCtD
Clomipramine—Epistaxis—Methotrexate—esophageal cancer	0.000152	0.00134	CcSEcCtD
Clomipramine—Vertigo—Capecitabine—esophageal cancer	0.000152	0.00134	CcSEcCtD
Clomipramine—Syncope—Capecitabine—esophageal cancer	0.000151	0.00134	CcSEcCtD
Clomipramine—Leukopenia—Capecitabine—esophageal cancer	0.000151	0.00134	CcSEcCtD
Clomipramine—Agranulocytosis—Methotrexate—esophageal cancer	0.00015	0.00133	CcSEcCtD
Clomipramine—Palpitations—Capecitabine—esophageal cancer	0.000149	0.00132	CcSEcCtD
Clomipramine—Loss of consciousness—Capecitabine—esophageal cancer	0.000148	0.00131	CcSEcCtD
Clomipramine—Body temperature increased—Cisplatin—esophageal cancer	0.000148	0.00131	CcSEcCtD
Clomipramine—Cough—Capecitabine—esophageal cancer	0.000147	0.0013	CcSEcCtD
Clomipramine—Hypertension—Capecitabine—esophageal cancer	0.000146	0.00129	CcSEcCtD
Clomipramine—Hepatitis—Methotrexate—esophageal cancer	0.000144	0.00128	CcSEcCtD
Clomipramine—Myalgia—Capecitabine—esophageal cancer	0.000144	0.00127	CcSEcCtD
Clomipramine—Chest pain—Capecitabine—esophageal cancer	0.000144	0.00127	CcSEcCtD
Clomipramine—Arthralgia—Capecitabine—esophageal cancer	0.000144	0.00127	CcSEcCtD
Clomipramine—Nortriptyline—PTGS1—esophageal cancer	0.000144	0.101	CrCbGaD
Clomipramine—Pharyngitis—Methotrexate—esophageal cancer	0.000143	0.00127	CcSEcCtD
Clomipramine—Anxiety—Capecitabine—esophageal cancer	0.000143	0.00127	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000143	0.00126	CcSEcCtD
Clomipramine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000143	0.00126	CcSEcCtD
Clomipramine—Discomfort—Capecitabine—esophageal cancer	0.000142	0.00126	CcSEcCtD
Clomipramine—Urethral disorder—Methotrexate—esophageal cancer	0.000141	0.00125	CcSEcCtD
Clomipramine—Dry mouth—Capecitabine—esophageal cancer	0.000141	0.00124	CcSEcCtD
Clomipramine—Visual impairment—Methotrexate—esophageal cancer	0.000139	0.00123	CcSEcCtD
Clomipramine—Confusional state—Capecitabine—esophageal cancer	0.000139	0.00123	CcSEcCtD
Clomipramine—Oedema—Capecitabine—esophageal cancer	0.000138	0.00122	CcSEcCtD
Clomipramine—Hypersensitivity—Cisplatin—esophageal cancer	0.000138	0.00122	CcSEcCtD
Clomipramine—Shock—Capecitabine—esophageal cancer	0.000136	0.0012	CcSEcCtD
Clomipramine—Nervous system disorder—Capecitabine—esophageal cancer	0.000135	0.0012	CcSEcCtD
Clomipramine—Eye disorder—Methotrexate—esophageal cancer	0.000135	0.00119	CcSEcCtD
Clomipramine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000135	0.00119	CcSEcCtD
Clomipramine—Tinnitus—Methotrexate—esophageal cancer	0.000135	0.00119	CcSEcCtD
Clomipramine—Tachycardia—Capecitabine—esophageal cancer	0.000134	0.00119	CcSEcCtD
Clomipramine—Asthenia—Cisplatin—esophageal cancer	0.000134	0.00119	CcSEcCtD
Clomipramine—Cardiac disorder—Methotrexate—esophageal cancer	0.000134	0.00119	CcSEcCtD
Clomipramine—Skin disorder—Capecitabine—esophageal cancer	0.000134	0.00118	CcSEcCtD
Clomipramine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000133	0.00118	CcSEcCtD
Clomipramine—Anorexia—Capecitabine—esophageal cancer	0.000131	0.00116	CcSEcCtD
Clomipramine—Angiopathy—Methotrexate—esophageal cancer	0.000131	0.00116	CcSEcCtD
Clomipramine—Immune system disorder—Methotrexate—esophageal cancer	0.00013	0.00115	CcSEcCtD
Clomipramine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00013	0.00115	CcSEcCtD
Clomipramine—Chills—Methotrexate—esophageal cancer	0.00013	0.00115	CcSEcCtD
Clomipramine—Hypotension—Capecitabine—esophageal cancer	0.000129	0.00114	CcSEcCtD
Clomipramine—Diarrhoea—Cisplatin—esophageal cancer	0.000128	0.00113	CcSEcCtD
Clomipramine—Alopecia—Methotrexate—esophageal cancer	0.000128	0.00113	CcSEcCtD
Clomipramine—Mental disorder—Methotrexate—esophageal cancer	0.000126	0.00112	CcSEcCtD
Clomipramine—Malnutrition—Methotrexate—esophageal cancer	0.000126	0.00111	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000126	0.00111	CcSEcCtD
Clomipramine—Insomnia—Capecitabine—esophageal cancer	0.000125	0.0011	CcSEcCtD
Clomipramine—Paraesthesia—Capecitabine—esophageal cancer	0.000124	0.0011	CcSEcCtD
Clomipramine—Dysgeusia—Methotrexate—esophageal cancer	0.000123	0.00109	CcSEcCtD
Clomipramine—Dyspnoea—Capecitabine—esophageal cancer	0.000123	0.00109	CcSEcCtD
Clomipramine—Back pain—Methotrexate—esophageal cancer	0.000122	0.00108	CcSEcCtD
Clomipramine—Dyspepsia—Capecitabine—esophageal cancer	0.000121	0.00107	CcSEcCtD
Clomipramine—Decreased appetite—Capecitabine—esophageal cancer	0.00012	0.00106	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000119	0.00105	CcSEcCtD
Clomipramine—Vomiting—Cisplatin—esophageal cancer	0.000119	0.00105	CcSEcCtD
Clomipramine—Fatigue—Capecitabine—esophageal cancer	0.000119	0.00105	CcSEcCtD
Clomipramine—Vision blurred—Methotrexate—esophageal cancer	0.000118	0.00105	CcSEcCtD
Clomipramine—Rash—Cisplatin—esophageal cancer	0.000118	0.00104	CcSEcCtD
Clomipramine—Constipation—Capecitabine—esophageal cancer	0.000118	0.00104	CcSEcCtD
Clomipramine—Pain—Capecitabine—esophageal cancer	0.000118	0.00104	CcSEcCtD
Clomipramine—Dermatitis—Cisplatin—esophageal cancer	0.000118	0.00104	CcSEcCtD
Clomipramine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000117	0.00103	CcSEcCtD
Clomipramine—Anaemia—Methotrexate—esophageal cancer	0.000116	0.00103	CcSEcCtD
Clomipramine—Feeling abnormal—Capecitabine—esophageal cancer	0.000114	0.00101	CcSEcCtD
Clomipramine—Malaise—Methotrexate—esophageal cancer	0.000113	0.001	CcSEcCtD
Clomipramine—Vertigo—Methotrexate—esophageal cancer	0.000113	0.001	CcSEcCtD
Clomipramine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000113	0.000997	CcSEcCtD
Clomipramine—Leukopenia—Methotrexate—esophageal cancer	0.000112	0.000996	CcSEcCtD
Clomipramine—Nausea—Cisplatin—esophageal cancer	0.000111	0.000983	CcSEcCtD
Clomipramine—Cough—Methotrexate—esophageal cancer	0.00011	0.000971	CcSEcCtD
Clomipramine—Urticaria—Capecitabine—esophageal cancer	0.000109	0.000969	CcSEcCtD
Clomipramine—Abdominal pain—Capecitabine—esophageal cancer	0.000109	0.000964	CcSEcCtD
Clomipramine—Body temperature increased—Capecitabine—esophageal cancer	0.000109	0.000964	CcSEcCtD
Clomipramine—Convulsion—Methotrexate—esophageal cancer	0.000109	0.000964	CcSEcCtD
Clomipramine—Diazepam—PTGS1—esophageal cancer	0.000109	0.0762	CrCbGaD
Clomipramine—Myalgia—Methotrexate—esophageal cancer	0.000107	0.000947	CcSEcCtD
Clomipramine—Chest pain—Methotrexate—esophageal cancer	0.000107	0.000947	CcSEcCtD
Clomipramine—Arthralgia—Methotrexate—esophageal cancer	0.000107	0.000947	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000106	0.000941	CcSEcCtD
Clomipramine—Discomfort—Methotrexate—esophageal cancer	0.000106	0.000936	CcSEcCtD
Clomipramine—Confusional state—Methotrexate—esophageal cancer	0.000103	0.000916	CcSEcCtD
Clomipramine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000103	0.000908	CcSEcCtD
Clomipramine—Triflupromazine—ABCB1—esophageal cancer	0.000102	0.0713	CrCbGaD
Clomipramine—Hypersensitivity—Capecitabine—esophageal cancer	0.000101	0.000899	CcSEcCtD
Clomipramine—Nervous system disorder—Methotrexate—esophageal cancer	0.000101	0.000891	CcSEcCtD
Clomipramine—Thrombocytopenia—Methotrexate—esophageal cancer	0.0001	0.000889	CcSEcCtD
Clomipramine—Skin disorder—Methotrexate—esophageal cancer	9.96e-05	0.000882	CcSEcCtD
Clomipramine—Hyperhidrosis—Methotrexate—esophageal cancer	9.91e-05	0.000878	CcSEcCtD
Clomipramine—Asthenia—Capecitabine—esophageal cancer	9.88e-05	0.000875	CcSEcCtD
Clomipramine—Anorexia—Methotrexate—esophageal cancer	9.78e-05	0.000866	CcSEcCtD
Clomipramine—Pruritus—Capecitabine—esophageal cancer	9.75e-05	0.000863	CcSEcCtD
Clomipramine—Hypotension—Methotrexate—esophageal cancer	9.58e-05	0.000849	CcSEcCtD
Clomipramine—Diarrhoea—Capecitabine—esophageal cancer	9.43e-05	0.000835	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.34e-05	0.000827	CcSEcCtD
Clomipramine—Insomnia—Methotrexate—esophageal cancer	9.28e-05	0.000821	CcSEcCtD
Clomipramine—Paraesthesia—Methotrexate—esophageal cancer	9.21e-05	0.000815	CcSEcCtD
Clomipramine—Dyspnoea—Methotrexate—esophageal cancer	9.14e-05	0.00081	CcSEcCtD
Clomipramine—Somnolence—Methotrexate—esophageal cancer	9.12e-05	0.000807	CcSEcCtD
Clomipramine—Dizziness—Capecitabine—esophageal cancer	9.11e-05	0.000807	CcSEcCtD
Clomipramine—Clobazam—ABCB1—esophageal cancer	9.04e-05	0.0634	CrCbGaD
Clomipramine—Dyspepsia—Methotrexate—esophageal cancer	9.03e-05	0.000799	CcSEcCtD
Clomipramine—Decreased appetite—Methotrexate—esophageal cancer	8.91e-05	0.000789	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.85e-05	0.000784	CcSEcCtD
Clomipramine—Fatigue—Methotrexate—esophageal cancer	8.84e-05	0.000783	CcSEcCtD
Clomipramine—Pain—Methotrexate—esophageal cancer	8.77e-05	0.000777	CcSEcCtD
Clomipramine—Vomiting—Capecitabine—esophageal cancer	8.76e-05	0.000776	CcSEcCtD
Clomipramine—Rash—Capecitabine—esophageal cancer	8.69e-05	0.000769	CcSEcCtD
Clomipramine—Dermatitis—Capecitabine—esophageal cancer	8.68e-05	0.000768	CcSEcCtD
Clomipramine—Headache—Capecitabine—esophageal cancer	8.63e-05	0.000764	CcSEcCtD
Clomipramine—Feeling abnormal—Methotrexate—esophageal cancer	8.45e-05	0.000748	CcSEcCtD
Clomipramine—Gastrointestinal pain—Methotrexate—esophageal cancer	8.39e-05	0.000743	CcSEcCtD
Clomipramine—Nausea—Capecitabine—esophageal cancer	8.18e-05	0.000725	CcSEcCtD
Clomipramine—Urticaria—Methotrexate—esophageal cancer	8.15e-05	0.000721	CcSEcCtD
Clomipramine—Body temperature increased—Methotrexate—esophageal cancer	8.11e-05	0.000718	CcSEcCtD
Clomipramine—Abdominal pain—Methotrexate—esophageal cancer	8.11e-05	0.000718	CcSEcCtD
Clomipramine—Hypersensitivity—Methotrexate—esophageal cancer	7.56e-05	0.000669	CcSEcCtD
Clomipramine—Asthenia—Methotrexate—esophageal cancer	7.36e-05	0.000652	CcSEcCtD
Clomipramine—Pruritus—Methotrexate—esophageal cancer	7.26e-05	0.000642	CcSEcCtD
Clomipramine—Chlorprothixene—ABCB1—esophageal cancer	7.11e-05	0.0499	CrCbGaD
Clomipramine—Diarrhoea—Methotrexate—esophageal cancer	7.02e-05	0.000621	CcSEcCtD
Clomipramine—Dizziness—Methotrexate—esophageal cancer	6.78e-05	0.0006	CcSEcCtD
Clomipramine—Flurazepam—ABCB1—esophageal cancer	6.64e-05	0.0466	CrCbGaD
Clomipramine—Trimipramine—ABCB1—esophageal cancer	6.57e-05	0.0461	CrCbGaD
Clomipramine—Vomiting—Methotrexate—esophageal cancer	6.52e-05	0.000577	CcSEcCtD
Clomipramine—Rash—Methotrexate—esophageal cancer	6.47e-05	0.000573	CcSEcCtD
Clomipramine—Dermatitis—Methotrexate—esophageal cancer	6.46e-05	0.000572	CcSEcCtD
Clomipramine—Headache—Methotrexate—esophageal cancer	6.42e-05	0.000569	CcSEcCtD
Clomipramine—Promethazine—ABCB1—esophageal cancer	6.33e-05	0.0444	CrCbGaD
Clomipramine—Doxepin—ABCB1—esophageal cancer	6.26e-05	0.044	CrCbGaD
Clomipramine—Trifluoperazine—ABCB1—esophageal cancer	6.24e-05	0.0438	CrCbGaD
Clomipramine—Nausea—Methotrexate—esophageal cancer	6.09e-05	0.000539	CcSEcCtD
Clomipramine—Desipramine—ABCB1—esophageal cancer	5.75e-05	0.0403	CrCbGaD
Clomipramine—Diazepam—ABCB1—esophageal cancer	5.28e-05	0.037	CrCbGaD
Clomipramine—Chlorpromazine—ABCB1—esophageal cancer	4.9e-05	0.0344	CrCbGaD
Clomipramine—Imipramine—ABCB1—esophageal cancer	4.87e-05	0.0342	CrCbGaD
Clomipramine—Amitriptyline—ABCB1—esophageal cancer	4.84e-05	0.034	CrCbGaD
Clomipramine—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.11e-05	0.000115	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	1.11e-05	0.000114	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	1.11e-05	0.000114	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.11e-05	0.000114	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—HIF1A—esophageal cancer	1.11e-05	0.000114	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.1e-05	0.000114	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	1.1e-05	0.000114	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.1e-05	0.000113	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—NOS3—esophageal cancer	1.09e-05	0.000113	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CYP19A1—esophageal cancer	1.07e-05	0.000111	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SST—esophageal cancer	1.07e-05	0.000111	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.07e-05	0.00011	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.07e-05	0.00011	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS1—esophageal cancer	1.06e-05	0.000109	CbGpPWpGaD
Clomipramine—ALB—Metabolism—ENO1—esophageal cancer	1.06e-05	0.000109	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.06e-05	0.000109	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—KDR—esophageal cancer	1.06e-05	0.000109	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—EP300—esophageal cancer	1.06e-05	0.000109	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	0.000109	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	1.05e-05	0.000109	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GNG7—esophageal cancer	1.05e-05	0.000108	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PSME2—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PSME1—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ALDH2—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.04e-05	0.000107	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ADH7—esophageal cancer	1.04e-05	0.000107	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	1.03e-05	0.000106	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	1.03e-05	0.000106	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.02e-05	0.000105	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TPI1—esophageal cancer	1.02e-05	0.000105	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.01e-05	0.000105	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—HIF1A—esophageal cancer	1.01e-05	0.000104	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—PIK3CA—esophageal cancer	1e-05	0.000104	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1e-05	0.000104	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.99e-06	0.000103	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	9.96e-06	0.000103	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	9.95e-06	0.000103	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSTT1—esophageal cancer	9.91e-06	0.000102	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—ERBB2—esophageal cancer	9.86e-06	0.000102	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.81e-06	0.000101	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—HMOX1—esophageal cancer	9.79e-06	0.000101	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP2A6—esophageal cancer	9.79e-06	0.000101	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALDOB—esophageal cancer	9.78e-06	0.000101	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—KDR—esophageal cancer	9.65e-06	9.97e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ENO1—esophageal cancer	9.51e-06	9.82e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS1—esophageal cancer	9.51e-06	9.82e-05	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—PIK3CA—esophageal cancer	9.5e-06	9.82e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GAPDH—esophageal cancer	9.41e-06	9.72e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—ABCB1—esophageal cancer	9.4e-06	9.71e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PSME2—esophageal cancer	9.37e-06	9.68e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PSME1—esophageal cancer	9.37e-06	9.68e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	9.36e-06	9.67e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSTT1—esophageal cancer	9.34e-06	9.64e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CRABP1—esophageal cancer	9.33e-06	9.64e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS1—esophageal cancer	9.28e-06	9.59e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ENO1—esophageal cancer	9.28e-06	9.59e-05	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.28e-06	9.58e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	9.23e-06	9.53e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PSME1—esophageal cancer	9.15e-06	9.45e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PSME2—esophageal cancer	9.15e-06	9.45e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	9.13e-06	9.43e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.12e-06	9.42e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ADH1B—esophageal cancer	9.11e-06	9.41e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NOTCH1—esophageal cancer	9.09e-06	9.39e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CREBBP—esophageal cancer	9.03e-06	9.33e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP1B1—esophageal cancer	9.01e-06	9.31e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GNG7—esophageal cancer	8.87e-06	9.17e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—EGFR—esophageal cancer	8.87e-06	9.16e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ENO1—esophageal cancer	8.75e-06	9.04e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.75e-06	9.04e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCND1—esophageal cancer	8.71e-06	9e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TYMP—esophageal cancer	8.7e-06	8.99e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	8.64e-06	8.92e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PSME2—esophageal cancer	8.62e-06	8.9e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PSME1—esophageal cancer	8.62e-06	8.9e-05	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	8.48e-06	8.76e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP19A1—esophageal cancer	8.47e-06	8.75e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.47e-06	8.75e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CDKN1A—esophageal cancer	8.43e-06	8.7e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—EP300—esophageal cancer	8.33e-06	8.6e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALDH2—esophageal cancer	8.31e-06	8.59e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	8.3e-06	8.58e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.25e-06	8.52e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	8.24e-06	8.51e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.18e-06	8.45e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	8.14e-06	8.41e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	8.1e-06	8.37e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	8.09e-06	8.35e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NOS3—esophageal cancer	8.08e-06	8.35e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EP300—esophageal cancer	8.02e-06	8.28e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTT1—esophageal cancer	7.91e-06	8.17e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.89e-06	8.15e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.87e-06	8.13e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TPI1—esophageal cancer	7.87e-06	8.13e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	7.86e-06	8.12e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	7.82e-06	8.07e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	7.81e-06	8.06e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.79e-06	8.04e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—KDR—esophageal cancer	7.79e-06	8.04e-05	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	7.74e-06	8e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—HMOX1—esophageal cancer	7.73e-06	7.98e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	7.7e-06	7.95e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	7.6e-06	7.85e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.58e-06	7.83e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ERBB2—esophageal cancer	7.56e-06	7.81e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—TP53—esophageal cancer	7.55e-06	7.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.55e-06	7.8e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.44e-06	7.68e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.42e-06	7.67e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—ABCB1—esophageal cancer	7.42e-06	7.66e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.41e-06	7.65e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ENO1—esophageal cancer	7.41e-06	7.65e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NOS3—esophageal cancer	7.38e-06	7.62e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	7.33e-06	7.58e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PSME1—esophageal cancer	7.3e-06	7.54e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PSME2—esophageal cancer	7.3e-06	7.54e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.26e-06	7.5e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.2e-06	7.44e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	7.07e-06	7.3e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	7.03e-06	7.26e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.99e-06	7.22e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MYC—esophageal cancer	6.99e-06	7.22e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—HMOX1—esophageal cancer	6.94e-06	7.17e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	6.9e-06	7.13e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GNG7—esophageal cancer	6.85e-06	7.07e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EGFR—esophageal cancer	6.83e-06	7.06e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.81e-06	7.03e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—HMOX1—esophageal cancer	6.77e-06	7e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—KDR—esophageal cancer	6.76e-06	6.98e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCND1—esophageal cancer	6.68e-06	6.9e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ABCB1—esophageal cancer	6.66e-06	6.88e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	6.65e-06	6.87e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	6.53e-06	6.75e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	6.46e-06	6.68e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	6.43e-06	6.64e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.42e-06	6.63e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.38e-06	6.59e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.38e-06	6.59e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	6.37e-06	6.58e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.3e-06	6.51e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CREBBP—esophageal cancer	6.28e-06	6.49e-05	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	6.24e-06	6.45e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—PIK3CA—esophageal cancer	6.16e-06	6.36e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	6.15e-06	6.35e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EP300—esophageal cancer	6.15e-06	6.35e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.13e-06	6.33e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.1e-06	6.3e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	6.1e-06	6.3e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.03e-06	6.23e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—esophageal cancer	5.96e-06	6.16e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	5.95e-06	6.15e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PIK3CA—esophageal cancer	5.93e-06	6.13e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.92e-06	6.12e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	5.9e-06	6.09e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	5.79e-06	5.98e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	5.77e-06	5.96e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—esophageal cancer	5.74e-06	5.93e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.72e-06	5.91e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ENO1—esophageal cancer	5.72e-06	5.91e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	5.67e-06	5.86e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	5.67e-06	5.86e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PSME2—esophageal cancer	5.64e-06	5.82e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PSME1—esophageal cancer	5.64e-06	5.82e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—NOS3—esophageal cancer	5.62e-06	5.81e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EP300—esophageal cancer	5.61e-06	5.8e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.61e-06	5.79e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	5.57e-06	5.75e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.42e-06	5.6e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.41e-06	5.58e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MYC—esophageal cancer	5.36e-06	5.54e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.3e-06	5.48e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	5.25e-06	5.43e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EGFR—esophageal cancer	5.24e-06	5.41e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.19e-06	5.36e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	5.17e-06	5.34e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	5.16e-06	5.33e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTGS2—esophageal cancer	5.14e-06	5.31e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.04e-06	5.2e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CREBBP—esophageal cancer	4.96e-06	5.12e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.93e-06	5.1e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	4.92e-06	5.09e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	4.92e-06	5.08e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MYC—esophageal cancer	4.89e-06	5.05e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.86e-06	5.02e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	4.84e-06	4.99e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	4.78e-06	4.94e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	4.76e-06	4.92e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	4.7e-06	4.86e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.57e-06	4.72e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	4.55e-06	4.7e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EP300—esophageal cancer	4.53e-06	4.68e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	4.48e-06	4.63e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CREBBP—esophageal cancer	4.45e-06	4.6e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—NOS3—esophageal cancer	4.44e-06	4.59e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—esophageal cancer	4.4e-06	4.55e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	4.4e-06	4.54e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CREBBP—esophageal cancer	4.34e-06	4.49e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—EP300—esophageal cancer	4.28e-06	4.42e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	4.27e-06	4.41e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.17e-06	4.31e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	4.15e-06	4.29e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	4.13e-06	4.27e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.09e-06	4.23e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS2—esophageal cancer	4.06e-06	4.19e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—esophageal cancer	4.02e-06	4.15e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ABCB1—esophageal cancer	4e-06	4.14e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NOS3—esophageal cancer	3.99e-06	4.12e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MYC—esophageal cancer	3.95e-06	4.08e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EP300—esophageal cancer	3.93e-06	4.06e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.92e-06	4.05e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NOS3—esophageal cancer	3.89e-06	4.02e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	3.89e-06	4.01e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	3.86e-06	3.99e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	3.76e-06	3.88e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.67e-06	3.79e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.64e-06	3.76e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	3.58e-06	3.7e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.56e-06	3.67e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.47e-06	3.58e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MYC—esophageal cancer	3.43e-06	3.54e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—EP300—esophageal cancer	3.38e-06	3.49e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.35e-06	3.46e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	3.35e-06	3.46e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	3.35e-06	3.46e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—esophageal cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	3.17e-06	3.27e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	3.12e-06	3.22e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NOS3—esophageal cancer	3.11e-06	3.21e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	3.05e-06	3.15e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—EP300—esophageal cancer	3.03e-06	3.13e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—EP300—esophageal cancer	2.96e-06	3.06e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.91e-06	3e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.84e-06	2.93e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.81e-06	2.91e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—EP300—esophageal cancer	2.79e-06	2.88e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.68e-06	2.76e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	2.65e-06	2.73e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	2.56e-06	2.64e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CA—esophageal cancer	2.5e-06	2.58e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.4e-06	2.48e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—EP300—esophageal cancer	2.36e-06	2.44e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.24e-06	2.32e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.06e-06	2.13e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—EP300—esophageal cancer	1.82e-06	1.88e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.75e-06	1.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.35e-06	1.39e-05	CbGpPWpGaD
